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Rationale: Patients with mild chronic obstructive pulmonary disease (COPD) present abnormal
ventilatory mechanics during exercise and may require bronchodilator therapy. However,
bronchodilation does not enhance cycling exercise tolerance in these patients whereas walking
may be more sensitive to the effects of bronchodilation.
Objectives: To characterize the impact of bronchodilation on i) exercise tolerance ii) cardio-
pulmonary response and iii) dynamic hyperinflation following an endurance shuttle walking
test in patients with mild COPD.
Methods: In a randomized double-blind cross-over trial, 37 patients with GOLD stage I COPD
(FEV1, 96  2% predicted, mean  SEM) completed an endurance shuttle walking test up to
exhaustion 90  15 min following nebulization of a placebo [NaCl] or of ipratropium
bromide/salbutamol sulfate (500 mg/2.5 mg) combination.
Results: FEV1 significantly increased following bronchodilation compared with placebo
(0.17  0.02 vs. 0.02  0.01 L, p < 0.0001, mean  SEM). The difference in walking endur-
ance time between bronchodilation and placebo was not statistically significant (D15  12 s,
pZ 0.21), with the upper and lower boundaries of the 95% confidence interval [9e40 s, 95%
CI] within the proposed minimally important difference for this variable (65 s). The ratio of
breathing frequency to tidal volume tended to be decreased with bronchodilation during
exercise (p Z 0.07), indicating a deeper and slower breathing pattern with bronchodilation.
Bronchodilation had a significant effect on dynamic hyperinflation at isotime and at peak
exercise.656 4747; fax: þ1 418 656 4762.
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TwQpot: potentiated quadriceps twitch force
SD standard deviation
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SpO2 pulse oxygen saturation
VC vital capacity
_VCO2 carbon dioxide output
_VE minute ventilation
_VO2 oxygen uptake
VT tidal volumeIntroduction
According to current treatment guidelines, patients with
mild (GOLD stage I) chronic obstructive pulmonary disease
(COPD) could be prescribed short-acting bronchodilators
treatment to relieve symptoms if considered appropriate by
the treating physician.1e3 There is currently a paucity of
data on the long-term safety and efficacy profiles of bron-
chodilator therapy in patients with mild COPD.4e6 The few
available studies nevertheless suggest that symptomatic
mild COPD patients may benefit from bronchodilator
therapy.4,7
Mild COPD patients may experience gas exchange
impairments,8 ventilatory inefficiency and dynamic hyper-
inflation during exercise,5 together resulting in exercise
intolerance. Bronchodilators play a pivotal role in
improving exercise capacity in moderate to severe
COPD,9e14 but little is known regarding their exercise
enhancing potential in mild COPD. A recent study evaluated
the impact of ipratropium bromide on exercise response in
symptomatic patients with GOLD stage I COPD.4 Even
though pulmonary function, operating lung volumes and
dyspnea were improved, bronchodilation did not increase
cycling endurance time. One potential explanation for this
negative observation is that peripheral muscle fatigue,
which is often seen during cycling, could have prevented
bronchodilation to translate into better endurance time.15Indeed, cycling was found to be less sensitive than
walking to detect changes in exercise performance after
bronchodilation, partially because quadriceps muscle
fatigue is more of an issue with this exercise modality than
with walking.14 Another appealing aspect of walking is that
it also more representative of daily life activities than
cycling.16
We hypothesized that walking may be a well suited
exercise testing modality to document possible improve-
ment in exercise capacity following bronchodilation in
patients with GOLD stage I COPD. Our general objective was
to characterize the impact of short-acting bronchodilation
on walking exercise tolerance in patients with GOLD stage I
COPD. We therefore compared the i) endurance time ii)
cardiopulmonary response and iii) dynamic hyperinflation
during an endurance shuttle walking test (ESWT) in patients
with mild COPD after either bronchodilation or placebo
inhalation.Methods
Ethics statement
The study was approved by the institutional ethics
committee (Comite´ d’e´thique, Institut Universitaire de
cardiologie et de pneumologie de Que´bec, approval 20378)
Walking exercise response in mild COPD 1697and all the participants signed an informed consent prior to
study enrollment. The research protocol was registered
[clinicaltrials.gov (NCT01360788)].
Subjects
Thirty-seven patients with GOLD stage I COPD (post-bron-
chodilator forced expiratory volume in 1 s [FEV1]  80%
predicted and FEV1/forced vital capacity [FVC] < 0.70)
1
and a significant smoking history (15 pack-years) were
recruited. Dyspnea degree was quantified by the Baseline
Dyspnea Index (BDI)17 and the Medical Research Council
(MRC) dyspnea score.18 Patients receiving bronchodilators
before the beginning of the study were asked to withdraw
from their medication 8 h in the case of short-acting
bronchodilators and/or 72 h in the case of long-acting
bronchodilators before the visits. Those treated with tio-
tropium had a 4-week washout period during which this
therapy was replaced by ipratropium bromide.
Participants were recruited following their recent
participation in COPD or lung cancer screening studies
(n Z 30) or following consultation with a chest physician
(n Z 7). Apart from the participation in screening studies,
none of the participants were involved in previous research
protocols. Subjects were excluded if they presented any
medical condition, other than COPD, likely to influence
muscle and exercise testing (i.e. cardiovascular, neurolog-
ical, musculoskeletal, locomotor or other respiratory
diseases as well as ß-blockers therapy). The flow chart of
the study is presented in Fig. 1.19 Subjects were asked to
avoid alcohol, caffeine and heavy meals 3 h before the visit
and high intensity physical activity for at least 24 h before
testing. Data reported were collected at the Institut Uni-
versitaire de cardiologie et de pneumologie de Que´bec.
Experimental visits were conducted at the same time of the
day for every subject.
Study design
This was a randomized, double blind, placebo-controlled
and cross-over trial. Study participation included threeFigure 1 Flow chart of the study according to CONSORT
guidelines. FEV1: Forced expiratory volume in 1 s; FVC: forced
vital capacity.distinct visits separated by 72 h and 7 days. During the
first visit, anthropometric measurements, complete
pulmonary function tests and symptom-limited incremental
shuttle walking test (ISWT) were completed. During this
visit, participants were also familiarized with the endur-
ance shuttle walking test (ESWT) to minimize learning
effects with this test.20 In the subsequent two visits (Fig. 2),
subjects entered a double-blind randomized cross-over
design where an endurance shuttle walking test (ESWT)
was performed up to exhaustion following either nebulized
ipratropium bromide 500 mg and salbutamol sulfate 2.5 mg
combination [CombiventUDV, Boehringer Ingelheim, Mis-
sissauga, Ontario, Canada] (BD) or nebulized isotonic
sodium chloride (placebo, PL). Spirometry was performed
at baseline and 60-min after nebulization. ESWT were
performed 90  15 min after nebulization. Prior to ESWT
and 10-min post-exercise, quadriceps muscle force was
quantified. A biostatistician determined the random allo-
cation sequence of placebo and bronchodilator using
a computer generated randomization list. Placebo and the
active medication were prepared by the study pharmacist
and had an identical appearance. Finally, the patients and
the technician in charge of all the investigation were blin-
ded from the experimental condition.
Pulmonary function testing
Spirometry, lung volumes and diffusion capacity (DLCO)
were obtained at baseline according to previously
described guidelines21 and related to predicted normal
values.22,23 The predicted value for inspiratory capacity (IC)
was obtained by subtracting the functional residual
capacity (FRC) predicted value from total lung capacity
(TLC) predicted value. The FEV1/FVC ratio was compared to
the lower limit of the normal (LLN) range according to the
NHANES III predicted values.23 Reported values were
measured after the inhalation of 400 mg of salbutamol in
every participant.24 Maximal voluntary ventilation (MVV)
was estimated by multiplying FEV1 by 35.
25Figure 2 Schematic representation of the experimental
protocol used for the two treatment visits. In a double-blind
randomized cross-over design, an endurance shuttle walking
test (ESWT) was performed following the inhalation of nebu-
lized placebo or a bronchodilator (BD) [ipratropium bromide
500 mg and salbutamol sulfate 2.5 mg combination]. Quadri-
ceps strength was measured before and after exercise by
magnetic stimulation of the femoral nerve (TwQpot).
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Incremental shuttle walking test (ISWT)
A symptom-limited incremental shuttle walking test was
realized in an enclosed corridor on a flat 10-m-long course.
The original protocol previously validated in COPD26 was
adapted to include 3 additional walking cadences in order
to allow every participant to reach symptom limitation.
During the test, subjects wore a facemask, linked to
a portable gas exchange analyzer (Oxycon Mobile, Viasys
Healthcare, Jaeger, Germany). Ventilation ( _VE), oxygen
consumption ( _VO2), CO2 output ( _VCO2) and respiratory
exchange ratio (RER) were monitored on a breath-by-
breath basis. Oxygen pulse saturation (SpO2) was
measured at baseline and during exercise using a pulse
oximeter (Nellcor N-395, Covidien, Boulder, CO, USA).
Blood pressure was measured manually at baseline and at
end-exercise. Dyspnea and leg fatigue Borg scores27 were
obtained at baseline and at end of exercise. A 12-lead
electrocardiogram (Cardiosoft, Corina, Milwaukee, WI,
USA) was used to monitor cardiac activity throughout
exercise. Patients were allowed to run in order to attain
maximal exercise capacity and standardized encourage-
ments were provided to the patients.
Endurance shuttle walking test (ESWT)
The test was realized with the same setting as the ISWT.
After a 90-sec warm-up phase, subjects were asked to
follow a fixed cadence until exhaustion, corresponding to
85% of the predetermined _VO2peak, as predicted from
incremental shuttle walking. The original protocol previ-
ously validated in moderate to severe COPD patients28 was
adapted to include 4 additional speed steps in order to
allow every participant to reach symptom limitation with
the ESWT. Patients were instructed to maintain the fixed
cadence for as long as possible and standardized instruc-
tions were given during the test in order to avoid any
potential effect on exercise performance.29 Endurance
time was defined as the duration of ESWT excluding the 90-s
warm-up period. As for ISWT, patients were allowed to run
to maintain the imposed cadence. Cardiorespiratory
response was monitored using the same setup as for ISWT
except that patients were asked to rate dyspnea and leg
fatigue perception every minute during the test. Inspiratory
capacity (IC) was measured at baseline, every 2-min during
exercise and at peak exercise following previously
described procedures.30Quadriceps muscle function
Potentiated quadriceps twitch force (TwQpot) of the domi-
nant leg was measured by supramaximal magnetic stimu-
lation of the femoral nerve 3 s following an isometric
maximal voluntary contraction of the quadriceps as previ-
ously reported.31 Each maneuver was separated by 30 s.
The reported values correspond to the mean of the three
strongest contractions for TwQpot. This was done in order to
ensure that peripheral muscle fatigue did not represent
a limiting factor to exercise. Quadriceps fatigue was
defined as a post-exercise fall in TwQpot > 15% resting
value.15Statistical analysis
All variables are expressed as means  SEM. _VE, _VO2, _VCO2,
heart rate (HR), tidal volume (VT), breathing frequency
(Bf), IC, SpO2 and oxygen pulse (O2 pulse) were compared at
rest between the two conditions using a paired t-test. The
time course of these parameters were also compared
during exercise between the two experimental conditions
using a mixed repeated analysis of variance (ANOVA). One
hundred percent isotime was defined as the latest exercise
time that was reached during the bronchodilation and
placebo conditions. Before and after the ESWT, muscle
force was compared using paired t-test. Pearson correla-
tions were performed to examine the association between
non-repeated measures. A statistical level of significance of
0.05 was used for all analysis. The data were analyzed using
the statistical package program JMP (Version 8.0.1, SAS
Institute Inc., Cary, NC ).
Since no data were available on the impact of bron-
chodilation on the endurance shuttle walking capacity in
mild COPD, the study sample size calculation was based on
the response in moderate to severe COPD patients14 and
the minimal important difference for this test previously
reported by our group.32 Accordingly, 45 patients were
necessary to detect a 65 s difference in walking endurance
between the two conditions with a SEM of change of 43 s
(aZ 0.05 and 1  bZ 0.80) in a cross-over trial. An interim
analysis was planned when 75% of the calculated sample
size was reached.Results
Subjects
Thirty-seven patients with mild COPD were randomized;
they all completed the study (Fig. 1). The recruitment and
testing period was from May 2009 and November 2010. We
stopped recruiting after the blinded interim analysis
revealed that the upper boundary of the 95% confidence
interval around the difference in endurance time between
the two experimental conditions was under the minimally
significant difference for this variable. Characteristics of
the participants are presented in Table 1. Diffusing lung
capacity was mildly reduced in these patients.
Spirometric response to bronchodilation
Spirometric values prior to nebulization at visit 2 and 3
were similar. The impacts of bronchodilation on resting
pulmonary function are presented in Fig. 3. The pre and
post treatment difference in FEV1 was significantly greater
with active bronchodilation when compared with placebo
(0.17  0.02 vs. 0.02  0.01 L, p < 0.0001, mean  SEM).
FVC and IC were not significantly modified by
bronchodilation.
Twenty seven percent of mild COPD patients met the
criteria defining a significant response to bronchodilation
(BD) (FEV1  12% and 200 mL).33 The average post-pre BD
FEV1 improvement in BD responders (n Z 10) was
0.34  0.03 L compared to 0.11  0.02 L (p < 0.001) in the
Table 1 Patient characteristics (n Z 37)
Age, yr 65  1
Male, % 70
BMI, kg/m2 27  1
Pack-years 43  4
BDI scale (0e12) 9.1  0.3
MRC scale (1e5) 1.6  0.1
Pulmonary function
FEV1, L 2.76  0.11
FEV1, % predicted 96  2
FVC, L 4.51  0.16
FVC, % predicted 117  2
FEV1/FVC, % 61  1
FEF25e75%, %predicted 43  2
IC, L 3.17  0.15
IC, % predicted 112  3
TLC, % predicted 111  2
FRC, % predicted 112  4
RV, % predicted 106  4
IC/TLC 0.47  0.01
DLCO, % predicted 82  3
Peak exercise capacity during ISWT
_VO2peak, mL $kg
1 $min1 25.6  0.8
_VO2peak, L $min
1 1.99  0.10
Exercise limiting symptoms during ISWT
Dyspnea, n (%) 23 (62)
Leg fatigue, n (%) 9 (24)
General fatigue, n (%) 5 (14)
Definitions of abbreviations: BMI Z body mass index;
BDIZ Baseline Dyspnea Index; MRCZ Medical Research Council
dyspnea scale; FEV1 Z forced expiratory volume in 1 s;
FVCZ forced vital capacity; FEF25e75% Z forced expiratory flow
between 25 and 75% of FVC; ICZ inspiratory capacity; TLCZ total
lung capacity; FRCZ functional residual capacity; RVZ residual
volume; DLCO Z diffusion capacity; ISWT Z incremental shuttle
walking test; _VO2 Z oxygen uptake. Values are mean  SEM.
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after bronchodilation was significantly higher in BD
responders than BD non-responders [DFVC (postepre BD),
0.28  0.14 vs. 0.05  0.05 L, p < 0.01]. The BD
responders were characterized by a more altered pulmo-
nary function and a more symptomatic profile as evidenced
by a lower FEV1 (88  3 vs. 99  2% pred., p < 0.01), FEV1/
FVC (55  2 vs. 64  1%, p < 0.001), DLCO (70  5 vs.
86  3% pred., p < 0.05) and BDI score (7.8  0.3 vs.
9.4  0.3, p < 0.01).Walking exercise endurance and bronchodilation
On average, bronchodilation did not significantly improve
endurance time during endurance shuttle walking (230  22
vs. 246  22 s, during placebo and active bronchodilation,
respectively) (Fig. 4, panel A). The mean difference
between the two treatments (BD-Placebo) was 15  12 s
(95% CI: 9e40 s) (Fig. 4, panel B).Physiological response to exercise
When comparing the impact of bronchodilation with
placebo, we found no difference in _VO2, _VCO2, HR and O2
pulse at the various timepoints (Table 2). The fall in SpO2
from baseline to peak exercise was significantly reduced
with active bronchodilation when compared with placebo
(0.9  0.4 vs. 2.2  0.6%, p < 0.01).
Ventilatory and breathing pattern responses during
walking are reported in Fig. 5. We found no differences in
the ventilatory response between the placebo and bron-
chodilation conditions. The ratio of breathing frequency to
tidal volume (Bf/VT) tended to be decreased with bron-
chodilation over the exercise period (p Z 0.07), reflecting
a deeper and slower breathing pattern with bronchodila-
tion. Finally, _VE/maximal voluntary ventilation (MVV) ratio
was reduced with bronchodilation.
Inspiratory capacity values at rest and during exercise
are shown in Fig. 5. Inspiratory capacity tended to be
higher after active bronchodilation than after placebo at
rest (p Z 0.11); this difference amounting to 100  80 mL
reached statistical significance at isotime and end-
exercise. The fall in inspiratory capacity from rest to end-
exercise was similar for the two experimental conditions
(0.59  0.07 L vs. 0.58  0.08 L).
Symptoms during exercise
No differences were found between bronchodilation and
placebo conditions either on dyspnea and leg fatigue
perceptions at isotime and at end-exercise (Fig. 5, panel
GeH ). The majority of patients stopped exercise because
of dyspnea (73% and 68% in the placebo and active bron-
chodilation conditions, respectively).
Quadriceps muscle fatigue
The fall in TwQpot occurring after ESWT were similar and
within the variability of the measurements in both experi-
mental conditions (9  1% and 8  1% after the placebo
and active bronchodilation conditions, respectively).
Quadriceps fatigue developed in 8 patients (22% of the
study population) after the placebo and/or bronchodilation
conditions, respectively.
Predictors of improvement in walking endurance
following bronchodilation
The extent of FEV1 response to bronchodilation was
heterogeneous (95% CI: 0.12e0.22 L). Ten patients met the
criteria defining a significant response to bronchodilation
(FEV1  12% and 200 mL).33 These patients did not exhibit
a larger improvement in walking endurance time when
compared to those who did not respond to bronchodilation
[D endurance time (bronchodilationeplacebo) Z 26  21
vs. 12  15 s for the bronchodilator responders and non-
responders, respectively, p Z 0.61]. A larger fall in inspi-
ratory capacity from rest to peak exercise, expressed in %
predicted or in L, was associated with a larger improvement
in walking endurance time with bronchodilation
[R Z 0.35, p < 0.05 (for IC % predicted); R Z 0.40,
Figure 3 Forced expiratory volume in 1 s (FEV1, panel A), forced vital capacity (FVC, panel B) and inspiratory capacity (IC, panel
C ) pre and 60-min post-nebulization of either placebo or bronchodilator (BD). Values are mean  SEM. **p < 0.0001 vs. pre-
bronchodilator measures and versus the post-pre BD changes seen in the placebo group.
Figure 4 Individual and group mean (SEM) walking endurance time following either placebo and bronchodilation (BD) inhalation
(panel A). Mean difference in walking endurance time between the two conditions with 95% confidence interval (panel B). The
dotted lines represent the minimal important difference (MID) of 65 s for the endurance shuttle walking test.
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Table 2 Isotime and peak physiologic response during
endurance shuttle walking test.
Mild COPD patients (n Z 37)
Placebo BD DBD-placebo
Isotime comparisons
_VO2, L/min
0% 0.99  0.05 0.90  0.04 0.08  0.03
25% 1.57  0.08 1.56  0.08 0.01  0.04
50% 1.79  0.09 1.77  0.09 0.03  0.05
75% 1.84  0.09 1.84  0.09 0.00  0.03
100% 1.85  0.09 1.86  0.09 0.01  0.02
Peak-exercise 1.84  0.09 1.91  0.09 0.04  0.03
_VCO2, L/min
0% 0.77  0.04 0.71  0.03 0.06  0.02
25% 1.43  0.09 1.39  0.08 0.03  0.04
50% 1.97  0.11 1.95  0.11 0.02  0.07
75% 2.24  0.13 2.17  0.12 0.07  0.06
100% 2.28  0.13 2.26  0.12 0.02  0.04
Peak-exercise 2.30  0.12 2.34  0.12 0.01  0.04
HR, beat/min
0% 95  2 95  2 1  1
25% 121  2 122  2 0  2
50% 140  2 140  3 0  2
75% 148  3 148  3 0  2
100% 151  3 151  3 0  2
Peak-exercise 151  2 153  3 1  1
O2 pulse, mL O2/beat
0% 10.0  0.5 9.3  0.5 0.7  0.4
25% 13.1  0.6 12.8  0.7 0.3  0.3
50% 12.8  0.6 12.4  0.6 0.3  0.3
75% 12.5  0.6 12.5  0.6 0.0  0.3
100% 12.3  0.6 12.4  0.7 0.1  0.2
Peak-exercise 12.2  0.6 12.5  0.6 0.1  0.2
Definitions of abbreviations: _VO2 Z oxygen uptake;
_VCO2 Z carbon dioxide output; _VE Z minute ventilation;
HR Z heart rate; O2 pulse Z _VO2/HR ratio. Values are
mean  SEM.
Walking exercise response in mild COPD 1701pZ 0.01 (for IC, L)]. However, the magnitude of increase in
inspiratory capacity during exercise with bronchodilation
did not predict the gain in endurance time improvement
following bronchodilation. We also stratified our cohort
according to the FEV1/FVC lower limit of the normal (LLN)
and to the development of quadriceps fatigue during
exercise (post-exercise fall in TwQpot > 15% resting value).
We found that bronchodilation did not increase walking
endurance, inspiratory capacity, nor improved exercise
physiological response even when considering only those
patients with an FEV1/FVC < LLN (n Z 29, D endurance
time [bronchodilationeplacebo]Z 10  14 vs. 35  22 s for
the patients with an FEV1/FVC < LLN and patients with an
FEV1/FVC > LLN, respectively, p Z 0.37). A similar
conclusion was reached when considering only patients who
did not develop quadriceps fatigue during placebo (nZ 29,
D endurance time (bronchodilationeplacebo)Z 23  25 vs.
14  14 s for the fatiguers and non-fatiguers, respectively,
p Z 0.38).Discussion
The present study investigated for the first time the impact
of bronchodilation on walking exercise tolerance in
patients with mild COPD. The main findings of this study
were that, in patients with mild COPD, acute bronchodila-
tion had modest physiological benefits during walking
including reduced operating lung volumes and a tendency
for improved breathing pattern. However, these physio-
logical benefits did not translate into better walking
endurance nor decreased dyspnea intensity during walking.Impact of bronchodilation on walking endurance
In contrast to our initial hypothesis, we found that bron-
chodilation did not significantly improve walking exercise
tolerance, even if this exercise modality may be more
sensitive than cycling to detect changes in exercise toler-
ance after bronchodilation in COPD14 and induces much less
fatigue of the legs than cycling.14,34 The observation of
a slight post-exercise reduction in the quadriceps twitch
force that was within the fatigue threshold for the whole
group and that only 22% of the study population developed
quadriceps fatigue, as compared to 50e60% during
cycling,14 is consistent with this last notion.15
The 95% confidence interval around the mean difference
in walking endurance time between bronchodilation and
placebo crossed zero and was within the suggested mini-
mally significant threshold for this variable (65 s).32 We can
thus conclude from this finding that acute bronchodilation
did not significantly improve walking endurance both from
a statistical and clinical standpoint. One patient dramati-
cally decreased endurance time with bronchodilation
(240 s). When excluding this patient from the analysis, the
difference in walking endurance between the two treat-
ments reached statistical significance (23  10 s [95% CI:
2e43 s], pZ 0.03] but the upper boundary of the 95% CI of
the difference was still smaller than 65 s. As such, the
conclusion about the inability of acute bronchodilation to
improve waking capacity beyond the minimally significant
threshold in patients with mild COPD remained unchanged.
This finding is consistent with a previous report showing
that acute bronchodilation did not enhance cycling endur-
ance in mild COPD.4
We considered the possibility that the absence of
improvement in exercise capacity could be related to
a suboptimal bronchodilation response. The absolute
improvement in FEV1 (170 mL) was comparable to what was
seen in previous trials demonstrating an improved walking
capacity after the administration of a single dose of ipra-
tropium bromide (180e190 mL) in patients with moderate
to severe COPD.14,20 However, when expressing this
response in % baseline FEV1, the magnitude of improvement
was much smaller in the present study (6%) than in previous
studies (12e14%).14,20 The likelihood that such a small
relative change in FEV1 translates into meaningful gains in
walking endurance appears to be small, particularly when
expiratory flows are well preserved, such as in mild COPD.
Response to bronchodilator therapy may be under-
estimated when solely looking at spirometric parameters as
hyperinflation and gas trapping can be improved with
Figure 5 Ventilation ( _VE, panel A), tidal volume reported as % of predicted vital capacity (VC) (VT, panel B), breathing frequency
(Bf, panel C ), breathing frequency to tidal volume ratio (Bf/VT, panel D) and ventilation to maximal voluntary ventilation ratio ( _VE
/MVV, panel E ) at 0%, 25%, 50%, 75%, 100% isotime and end-exercise. Inspiratory capacity (IC, panel F ) at baseline, 2-min and end-
exercise. Leg fatigue (panel G) and dyspnea (panel H ) Borg scores at baseline, 1-min, isotime and end-exercise. Submaximal
(circles) and end-exercise (diamonds) values are represented for placebo (open symbols) and bronchodilator (closed symbols)
conditions. Values are mean  SEM. * Indicates that the time course was statistically different (p < 0.05) between the 2 conditions;
yp < 0.05 vs. placebo condition at a given time point.
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Similarly to a previous investigation conducted in mild
COPD,4 inspiratory capacity was not improved following
bronchodilation, suggesting that a reduction in resting lung
volumes did not occur in our patients. This finding is ex-
pected when considering the normal baseline inspiratorycapacity and lung volumes in our study population. This
situation contrasts with previous studies confirming the
possibility to enhance exercise capacity with bronchodila-
tion in moderate to severe COPD in whom static hyperin-
flation (FRC  120% predicted) was a prerequisite for
participation.9e12 Considering that reducing operating lung
Walking exercise response in mild COPD 1703volume during exercise is a key determinant of the exercise
response to bronchodilation, the low levels of static
hyperinflation in our patients could be partly responsible
for the lack of improvement in exercise following
bronchodilation.
The small physiological improvements that were
observed during exercise with bronchodilation were
entirely consistent with the expected benefits of this class
of pharmacological agents.11,36,37 They were also consistent
in direction and magnitude to what was reported in
a similar investigation of bronchodilation during cycling
exercise in patients with GOLD I COPD.4 Among the physi-
ological improvements seen with therapy, there was a slight
reduction in dynamic hyperinflation at isotime indicating
that patients were breathing at lower lung volumes.37 As
expected from bronchodilators,10,11 this small reduction in
dynamic hyperinflation was mainly a reflection of lung
deflation at rest with bronchodilators since the slope of the
fall in inspiratory capacity over time was not modified with
therapy. In this context, the tendency for a slower and
deeper breathing pattern was likely related to reduced
mechanical constraint and operating lung volumes during
exercise.37 The ventilatory reserve was also improved with
bronchodilation, a direct consequence of an improved FEV1
since ventilation was unchanged with therapy.
The clinical relevance of these physiological improve-
ments with bronchodilation remain uncertain because they
did not translate into better walking endurance nor in
reduced dyspnea perception. In fact, these physiological
changes were likely too small to translate into clinical
benefits. For example, in patients with GOLD IIeIII COPD,
reductions in inspiratory capacity at isotime in the order of
200 mL (about twice as much as was is found in GOLD I)
have been associated with reduced exertional dyspnea and
prolonged exercise endurance.10,11 Interestingly, the
observation that patients experiencing the largest fall in
inspiratory capacity during exercise were the most likely to
improve walking capacity following bronchodilation
suggests that a more severe degree of hyperinflation at
baseline could have been associated with a greater exercise
response to bronchodilation.Methodological considerations
We used the GOLD classification to stratify our patients
because of its wide clinical application. This classification
could lead to potential misdiagnosis, especially in elderly
patients.38 To address this potential limitation, we also
stratified our cohort according to the FEV1/FVC lower limit
of the normal and found that bronchodilation did not
increase walking endurance, inspiratory capacity, nor
improved exercise physiological response even when
considering only those patients with an FEV1/FVC < lower
limit of the normal (n Z 29).
Compared to stationary cycling exercise, measuring
symptom perception and dynamic hyperinflation is more
challenging during walking. However, we are confident that
our measurements were reliable. Patients were familiarized
with all study procedures. Measurements of inspiratory
capacity were done with direct inspection of the flow/
volume loops and only measurements that were performedwith optimal inspiratory efforts when a stable end-
expiratory volume could be established were considered
for analysis. We acknowledge that complete pulmonary
function tests, including lung volume measurements, could
have been useful to further document the impact of bron-
chodilation on lung hyperinflation in our patients. Lastly, this
study does not exclude the possibility that more potent and/
or longer duration of bronchodilation could be associated
with larger improvement in exercise capacity in mild COPD.
In conclusion, bronchodilation did not improve walking
endurance in patients with mild COPD during walking
exercise despite small beneficial effects on dynamic
hyperinflation and breathing pattern during exercise.
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